Stephane CastelinVariant BioVariant Bio Turns FiveReflections on our drug discovery journey from co-founder Stephane CastelAug 31, 2023Aug 31, 2023
Stephane CastelinVariant BioVariant Bio’s Data and Sample Governance Principles and CommitmentsSharing our approach to data and sample governance in partnerships around the worldApr 5, 2023Apr 5, 2023
Stephane CastelinVariant BioIntroducing New Members of Variant Bio’s Scientific Advisory BoardFour scientists, Drs. Evan Eichler, Gosia Trynka, Ryan Hernandez, and Tuuli Lappalainen, join a prominent team of experts to advise VariantMar 29, 2022Mar 29, 2022
Stephane CastelinVariant BioThe GTEx Project: A Big Step Towards Understanding the Regulatory GenomeHow the postdoctoral work of Stephane Castel, co-founder of Variant Bio, helped advance knowledge around the ways that trait-associated…Sep 10, 2020Sep 10, 2020
Stephane CastelinVariant BioHIV Resistance, CRISPR Babies, and a Potential COVID-19 Treatment: The Story of the Infamous…How a single mutation gained notoriety for HIV resistance, CRISPR gene editing in China, and now an experimental drug program for Covid-19Apr 22, 2020Apr 22, 2020
Stephane CastelinVariant BioVariant at AWS re:Invent Biotech 2019Stephane presents “From Remote Villages to New Therapies through Cloud-based Genomics” at AWS re:Invent Biotech 2019Feb 19, 2020Feb 19, 2020
Stephane CastelinVariant BioAfrican-Enriched Genetic Variants Hold the Key to Treating High CholesterolCholesterol, the PCSK9 gene, and the importance of including people of diverse ancestry in genetic studiesJan 29, 2020Jan 29, 2020
